Posted 9/8/2023, 5:54:50 PM

Morgan Stanley and JPMorgan Update Stock Picks: Gilead, Apple, Cloud Data Providers in Focus

Morgan Stanley updated its top stock picks that outperformed the market last year
The picks include companies like Gilead Sciences, Apple, and cloud data providers
Gilead could jump 30% as biopharma rebounds, says Bank of America
JPMorgan trimmed Apple's price target ahead of iPhone 15 launch
D.A. Davidson says a cloud data provider will benefit from AI

cnbc.com

Relevant topic timeline:

8/21/2023

3 Reasons Why The Biopharma M&A Market Is Ready For Takeoff

M&A activity in the healthcare sector has been slow in 2023, but experts predict an influx of biopharma M&A deals in the second half of the year due to a looming patent cliff, low valuations, and a weak IPO market. Several large pharmaceutical companies are seeking late-stage assets to offset revenue decline from expiring patents. The low valuations of biotech companies make them attractive to buyers, and the slow IPO market further drives M&A activity. However, antitrust scrutiny from federal regulators could pose a potential challenge.

9/11/2023

Analysts Predict Big Gains for Johnson & Johnson Spinoff, Tesla, and Gilead Sciences Stocks

Morgan Stanley upgrades Tesla and makes it a top pick with analyst Adam Jonas predicting a 60% rally, while Gilead Sciences could jump nearly 30% as biopharma bounces back, says Bank of America.